| Literature DB >> 27572640 |
Bram Van den Bergh1, Joran E Michiels1, Tom Wenseleers2, Etthel M Windels1, Pieterjan Vanden Boer1, Donaat Kestemont1, Luc De Meester3, Kevin J Verstrepen1,4, Natalie Verstraeten1, Maarten Fauvart1,5, Jan Michiels1.
Abstract
The evolution of antibiotic resistance is a major threat to society and has been predicted to lead to 10 million casualties annually by 2050(1). Further aggravating the problem, multidrug tolerance in bacteria not only relies on the build-up of resistance mutations, but also on some cells epigenetically switching to a non-growing antibiotic-tolerant 'persister' state(2-6). Yet, despite its importance, we know little of how persistence evolves in the face of antibiotic treatment(7). Our evolution experiments in Escherichia coli demonstrate that extremely high levels of multidrug tolerance (20-100%) are achieved by single point mutations in one of several genes and readily emerge under conditions approximating clinical, once-daily dosing schemes. In contrast, reversion to low persistence in the absence of antibiotic treatment is relatively slow and only partially effective. Moreover, and in support of previous mathematical models(8-10), we show that bacterial persistence quickly adapts to drug treatment frequency and that the observed rates of switching to the persister state can be understood in the context of 'bet-hedging' theory. We conclude that persistence is a major component of the evolutionary response to antibiotics that urgently needs to be considered in both diagnostic testing and treatment design in the battle against multidrug tolerance.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27572640 DOI: 10.1038/nmicrobiol.2016.20
Source DB: PubMed Journal: Nat Microbiol ISSN: 2058-5276 Impact factor: 17.745